Hemispherx Biopharma HEB announced that at the 53rd annual meeting of Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado during
September 9-13, 2013, that William Mitchell, MD, Ph.D., Professor Pathology,
Microbiology, and Immunology, Vanderbilt University, presented the results of
a study of Hemispherx product, Alferon N Injection^®, the only multi-species,
natural interferon approved in the U.S. for the treatment of human refractory
HPV genital warts, against wild type and oseltamivir (Tamiflu)-resistant H7N9
influenza virus.
The increasing prevalence of oseltamivir-resistant Influenza A Virus,
particularly against H7N9, has been widely reported and is due in large part
to the fact that just a single-step mutation in this genetically unstable
virus makes it resistant to oseltamivir. Dr. Mitchell, who is member of the
Board of Directors of Hemispherx, discussed new experiments on the inhibition
of Tamiflu^®-resistant H7N9 virus by Alferon N Injection^®.
These experiments were conducted at Kansas State University by Professor
Juergen Richt, DVM, Ph.D., Director of the U.S. Department of Homeland
Security Center of Excellence for Emerging and Zoonotic Animal Diseases
(CEEZAD), Regents Distinguished Professor of Veterinary Medicine at Kansas
State University and an Eminent Scholar of Kansas Bioscience Association (KBA)
along with his staff.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in